MétaCan
Menu
Back to cohort
Record W4214573195 · doi:10.1038/s43018-022-00332-x

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

2022· article· en· W4214573195 on OpenAlexfundno aff
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adrià López‐Fernández, Markus Jonsson, Ali Razzak, Irene Braña, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martín-Romano, Frans L. Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Shubha Anand, Danny Baars, Svetlana Bajalica‐Lagercrantz, Mariska Bierkens, Lennart Blomqvist, Costanza Bono, Gary J. Doherty, A Forest, Valentina Fornerone, Paola Gabaldi, Felix Haglund, Johan Hartman, Peter Horak, Tanja Jutzi, Mary Kasanicki, Simon Kreutzfeldt, Lucian Le Cornet, Rolf Lewensohn, Johan Lindberg, Carlos López, Andreas Lundqvist, Jose‐Ezequiel Martín, Gerrit A. Meijer, Susana Muñoz, Maud Ngo Camus, Claudio Nicotra, Paolo Nucíforo, Petra Oberrauch, Päivi Östling, Laura Pelz, Alejandro Piris‐Giménez, Elena Provenzano, Étienne Rouleau, John Rowell, Omar Saavedra, Giovanni Scoazec, Kenneth B. Seamon, Marc Tischkowitz, Lizet van der Kolk, Ruud van der Noll, María Vieito, Daniël J. Vis, Ana Vivancos, Christina von Gertten, Anders Wennborg, Lodewyk F.A. Wessels, Valtteri Wirta, Judith Balmañà, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Fröhling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile E. Voest, Jordi Rodón, Janne Lehtiö

Bibliographic record

VenueNature Cancer · 2022
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsnot available
FundersPrincipia BiopharmaLoxo OncologyPharmacyclicsChugai PharmaceuticalGenentechFoundation MedicineSierra OncologyMenarini GroupPharmaMarNovartis FarmacéuticaDaiichi Sankyo EuropeServierStockholms Läns LandstingKarolinska InstitutetEisaiFundación Bancaria Caixa d'Estalvis i Pensions de BarcelonaNational Institute for Health and Care ResearchEuropean Bioinformatics InstituteSeagenMacroGenicsBeiGeneMedical Research CouncilLes Laboratories Pierre FabreUniversity of CambridgeCancer Research UKSpectrum PharmaceuticalsIpsenArray BioPharmaSymphogenPfizerIncyteF. Hoffmann-La RocheEuropean CommissionScience for Life LaboratoryHalozymeExelixisSanofiGlaxoSmithKlineAmgenCelgeneAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsPrecision oncologyMedical physicsClinical OncologyMedicineOncologyInternal medicineCancer

Abstract

fetched live from OpenAlex

There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.014
metaresearch head score (Gemma)0.046
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.045
Threshold uncertainty score0.151

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0140.046
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0040.003
Science and technology studies0.0010.001
Scholarly communication0.0070.007
Open science0.0020.007
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0450.023

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.386
Teacher spread0.369 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations130
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueNature CancerSame topicCancer Genomics and DiagnosticsFrench-language works237,207